Xbira, containing the active ingredient Abiraterone, is a medication used in the treatment of prostate cancer. It belongs to a class of drugs known as androgen biosynthesis inhibitors, which work by inhibiting the production of androgens (male hormones) in the body, thereby slowing the growth and spread of prostate cancer cells. Here is a detailed description:

1. Active Ingredient:

• Abiraterone: Abiraterone is a selective and irreversible inhibitor of the enzyme CYP17A1 (17α-hydroxylase/C17,20-lyase), which is involved in the biosynthesis of androgens in the adrenal glands, testes, and prostate tumor tissue.

2. Indications:

• Metastatic Castration-Resistant Prostate Cancer (mCRPC): Xbira is indicated for use in combination with prednisone or prednisolone for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in adult men who have received prior chemotherapy containing docetaxel.

3. Dosage:

• Xbira is available in tablet form with a strength of 250 mg.
• The recommended dosage is typically 1000 mg (four tablets) taken once daily in combination with prednisone or prednisolone.

4. Administration:

• The tablets should be taken orally with water, preferably on an empty stomach, at least one hour before or two hours after eating.
• It’s essential to follow the prescribed dosage and administration schedule provided by a healthcare professional.

5. Effectiveness:

• Clinical trials have demonstrated that Xbira, when used in combination with prednisone or prednisolone, can improve overall survival and delay disease progression in patients with metastatic castration-resistant prostate cancer.

6. Safety Profile:

• Common side effects may include fatigue, hypertension, hypokalemia (low potassium levels), fluid retention, liver function abnormalities, and cardiac disorders.
• Regular monitoring of blood pressure, electrolytes, liver function, and cardiac function may be necessary during treatment with Xbira.

7. Contraindications:

• Xbira is generally contraindicated in individuals with a known hypersensitivity to Abiraterone or any of the components of the medication.

8. Precautions:

• Xbira should be used with caution in patients with a history of cardiovascular disease, hepatic impairment, or electrolyte abnormalities.
• Close monitoring and appropriate management are required for patients with comorbid conditions or those taking other medications that may interact with Abiraterone.

9. Follow-Up Care:

• Patients receiving Xbira will likely undergo regular follow-up visits with their healthcare provider to assess treatment response, monitor for side effects, and make any necessary adjustments to the treatment plan.

Xbira (Abiraterone) represents an important treatment option for patients with metastatic castration-resistant prostate cancer, providing a targeted approach to inhibit androgen synthesis and slow disease progression. Treatment decisions should be made in consultation with a qualified healthcare professional, taking into account the individual patient’s health status and treatment goals.